Oalib Open Access Library Journal 2333-9705 2333-9721 Scientific Research Publishing 10.4236/oalib.1114570 Oalib-147599 Articles Biomedical Life Sciences, Business Economics, Chemistry Materials Science, Computer Science Communications, Earth Environmental Sciences, Engineering, Medicine Healthcare, Physics Mathematics, Social Sciences Humanities Interaction between Malassezia and Novel Therapeutic Agents in Chronic Inflammatory Cutaneous Conditions Edosa Derartu Shumet Yi Sun aDepartment of Dermatology, Hubei Provincial Clinical Research Center for Diagnosis and Therapeutics of Pathogenic Fungal Infection, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, China 31 10 2025 12 11 1 19 7, November 2025 24, November 2025 24, November 2025 © Copyright 2014 by authors and Scientific Research Publishing Inc. 2014 This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Chronic inflammatory cutaneous diseases, such as atopic dermatitis (AD) and psoriasis, are complex disorders influenced by immune dysregulation, various genetic factors, and more recently identified alterations within the skin microbiome. Among the skin’s commensal organisms, Malassezia species play a significant role in modulating both skin inflammation and barrier function. These fungi are normally harmless; becoming pathogenic under specific immune or environmental conditions is one of the proposed mechanisms of disease exacerbation. Recent advances in treatment, with biologic agents and smaller molecule therapies, have revolutionized disease management by precisely targeting certain immune pathways (IL-4, IL-13, IL-17, IL-23, and JAK-STAT cascade) being the primary focus of these interventions. The subsequent effects that such targeted therapies have on the skin microbiome itself, Malassezia included, are yet to be fully understood. Emerging evidence points towards biologics and/or novel treatments altering the local immune environment and to some degree skin barrier integrity, which in turn affects microbial composition and activity. This review details the current knowledge of Malassezia distribution and behavior in AD and psoriasis patients, their immune interactions, and potential impact of the novel therapies on malassezia. Personalized, microbiome conscious, therapeutic approaches are the end goal, improving treatment outcome and long term skin health in patients with chronic inflammatory skin disease. Subject AreasDermatology Malassezia Skin Microbiome Atopic Dermatitis Psoriasis Biologic Therapies 1. 引言近年来，随着多媒体技术和经济多元全球化的不断发展，跨界思维不断冲击着传统的品牌联合，电商、餐饮、服装等行业相继掀起跨界联合风潮，营销学之父菲利普·科特勒曾经说过：除了主流品牌和小众品牌以外，混合品牌也将在未来占据一席之地，其中这个混合品牌与后面的“跨界品牌联合”在某种程度上是一样的，跨界品牌联合是指处于不同行业边界的品牌跨边界进行合作共同推出新产品 [1] 。在跨界联合的实践过程中有的品牌跨界备受关注，溢出效应明显，例如Rio华为手机结合保时捷设计出的超级旗舰MateRS设计好评如潮，大白兔品牌奶糖与加美净这类日化品牌推出的奶糖味的唇膏，上架即一扫而光，然而有的跨界联合却反响平平，甚至出现负面溢出效果，例如喜茶与杜蕾斯的联合产品没有得到消费者的积极评价，甚至使消费者产生反感情绪。之前关于品牌联合效果影响因素的分析上主要体现在联合匹配性、在产品关系和逻辑上的契合度，以及品牌要素互补性方面，但是在研究跨界联合时没有考虑到跨界品牌双方本身就具有较大的差异性，所以在一定程度上对跨界联合的成败现象并不能完全解释。因此，本文聚焦品牌跨界联合情景下，根据形式与功能的整合程度将品牌跨界联合的整合度分为高、低两种，基于SOR模型 [2] ，进而分析品牌跨界联合时的整合度高低对消费者品牌联合评价的影响机制，并且在这个基础上研究消费者感知价值在品牌跨界联合时的整合度对消费者品牌联合评价的中介作用。 2. 文献回顾及研究假设(一) 品牌跨界联合整合度与消费者品牌联合评价相关研究有关品牌跨界联合的概念大多围绕跨界营销进行，在市场营销中有共生营销的概念，它是指一种合作联盟关系，合作双方及多方为实现资源共享，提升竞争能力而形成的一种长期或者短期联盟合作关系，而品牌跨界联合则是指两个异质行业、互相独立但拥有平等商业地位的品牌通过活化老品牌，共享互补资源，降低成本等方式以推出新产品，从而实现销售额的增加 [3] 。两者具有一定的相似性，因此根据前人的论述及本文的研究内容将品牌跨界联合大致定义为品牌联合的特殊形式，是指同一个新的产品中存有两个来自不同且没有竞争关系行业的品牌。由于合作品牌双方的合作程度对消费者的品牌评价会产生相应的影响，Newmeyer等(2018) [4] 根据联合产品在形式和功能上的结合程度提出了六种整合度不同的品牌联合形式，从低到高依次为同地品牌联合、共同促销、捆绑联合、成分联合、要素联合、共同研发联合，本文根据形式和功能的结合程度，将共同研发联合和元素联合划分为高度整合，成分联合和捆绑联合划分为中度整合，共同促销和同地品牌联合划分为低度整合。一个品牌产品所带来的功能或者形式较为单一，不能满足消费者日益多元的功能需求和价值需求，如果将两个异质性产品进行跨界联合，不仅能够带来冲击固有认知的创新感，还有益于提升消费者的忠诚度，但是差异过大的品牌联合可能会产生负面溢出效应 [5] 。所以大多学者聚焦于品牌跨界联合前的联合匹配性和契合度的研究，忽视了品牌跨界联合过程中的整合程度，而消费者对跨界品牌联合的评价在一定层面上反映出跨界联合双方合作的效果，较高的评价不仅有助于维持对品牌资产较好品牌的忠诚度，还有利于提升品牌资产较弱一方的品牌形象(Lin, 2013)，在跨界品牌联合中合作双方的交融程度越深，即产品整合度越高，越有益于消费者体验到品牌双方各自的优势，感受到跨界联合产品所带来的新奇与价值感，从而促进消费者对跨界品牌联合作出积极评价。综上所述，本文提出假设1：H1：在品牌跨界联合时，产品整合度对品牌联合评价有正向影响。(二) 在品牌跨界联合时，感知价值在产品联合整合度对品牌联合评价中的中介作用消费者感知价值这一概念是基于现代营销中的消费者价值理论，该理论认为营销其实是交换价值与感知价值的过程，消费者在得到产品后会对其付出成本与感知价值效用进行比较，从而给出整体评价 [6] 。消费者感知价值时往往有三个特征，对产品价值会根据自身主观性进行感知，并且倾向于在比较中感知价值，其感知的价值还具有阶梯性 [7] 。因此，范秀成等(2003) [8] 将消费者感知价值概述为消费者对企业提供的产品和服务价值的主观评价，当消费者感知到价值时会对品牌联合产生积极评价，而产品整合度越高，即跨界联合产品无论是形式还是功能方面都高度融合，没有令消费者产生突兀感，能够驱动消费者产生价值感知，将异质的产品进行创新融合，起初的不匹配性能够打破了对原有品牌的刻板印象，再通过后面的高度整合能够使消费者产生创新感知的同时降低跨界创新产品的不确定性，感受到品牌联合带来的综合价值，而消费者的感知价值会影响消费者对品牌的选择，进而促进消费者对品牌联合作出正向评价 [9] 。因此，本文假设在品牌跨界联合过程中，合作双方后期在形式和功能上的产品整合度将影响消费者感知价值，又因为高整合度与品牌联合评价具有正向影响，推测消费者感知价值也将正向影响品牌联合评价。综上所述，本文提出假设2：H2：在品牌跨界联合时，消费者感知价值在产品整合度对消费者品牌联合评价的影响中起到中介作用。基于此，本文以SOR模型为研究框架，将品牌框架联合时的产品整合度作为刺激源，消费者从中获得的价值感知作为个体心理呈现，消费者对品牌联合的评价作为消费者者反应，构建在品牌跨界联合中产品整合程度对品牌联合评价的影响模型，模型如 图1 所示。 <xref ref-type="bibr" rid="oalib.147599-"></xref>Figure 1. Research model图1. 研究模型 图1. 研究模型 3. 实证设计与研究发现1) 研究设计与数据收集这部分由前测和正式实验组成，前测主要是通过了解市场上影响较广的跨界联合产品，并由此确定实验对象，正式实验根据产品组合利用单因素两水平，即产品整合程度高低的组间设计，检验品牌跨界联合时产品整合程度对品牌联合评价的主要影响以及消费者价值感知对其中的中介效应。① 前测。通过网络咨询了解与品牌跨界词条有关的内容，其中包含了有关跨界产品组合功能与形式的324条记录。选择了6组市面上真实的跨界组合案例，分别为蔻驰皮革的贝克家具、加入当尼柔顺剂的汰渍洗衣液、安装劳斯莱斯发动机的空客机、戴尔电脑与佳能打印机、配有迪士尼玩具的儿童餐、出售赛百味三明治的沃尔玛。通过变动产品整合度的操纵方法，让受访者填写整合度的7级量表 [4] ，对这些组合的产品整合度进行打分。此次前测收回有效问卷78份，并通过统计数据分析得出，蔻驰皮革的贝克家具这组共同研发组合的整合度评分均值为M 整合度 = 5.26，出售赛百味三明治的沃尔玛这组同地品牌联合销售的整合度评分均值为M 整合度 = 4.14，两者之间的差异很明显，将蔻驰皮革的贝克家具作为高整合度组合，而将出售赛百味三明治的沃尔玛作为低整合度组合，并将两组组合作为实验的刺激源。② 正式实验。该实验采用单因素两水平的设计，包括了102名消费者，其中人员年龄集中于26~35岁，男性占比42.15%，女性占比57.85%，教育程度占比主要是本科学历，将被试进行随机等量分配，其中高低整合度组各自均为61人。让产品高整合度组的被试浏览蔻驰皮革的贝克家具在功能和形式上的整合材料信息，同时让产品低整合度组的被试浏览沃尔玛出售赛百味三明治的销售整合信息，两组被试在看到品牌跨界联合刺激材料后如实填写产品感知价值量表以及品牌联合评价量表，具体量表题项如 表1 所示。 <xref ref-type="bibr" rid="oalib.147599-"></xref>Table 1. Measurement scaleTable 1. Measurement scale 表1. 测量量表

测量维度

测量题项参考来源

消费者感知价值

讨论/拥有/分享这项联名让我很开心

李慧，周雨(2021)

讨论/拥有/分享这项联名让我给他人留下了好印象

这项联名让我获得了自我满足

Sweeney and Soutar (2001)

该联名是我喜欢的

讨论/拥有/分享这项联名让我结识了很多朋友

品牌联合评价

我认为该产品很吸引人

Shih等(2013)

我非常喜欢该联合产品

该联合产品表达了我的个性
2) 数据分析① 问卷的信效度检验。利用SPSS 24.0对实验中的数据进行信度与效度的检验，其中产品感知价值量表以及品牌联合评价量表的Cronbach’ α系数分别为0.891、0.912，两者均在0.8以上，说明问卷信度较好。同时，通过验证性因子分析得出组合的CR和AVE值，从中发现组合效度AR值大于0.7，说明所选题项的一致性好，AVE值也达到了推荐的标准，所以该变量具有较好的效度。②主效应检验。在品牌跨界联合中，通过独立样本T检验验证产品整合度对消费者品牌联合评价有显著影响，即主效应检验。如 表2 所示，产品整合度不同，消费者对品牌跨界联合评价也显著不同，在产品整合度较高的跨界联合中，消费者对品牌联合评价(M = 2.811)显著高于产品整合度低的跨界联合产品(M = 1.649)，因此本文的假设1得到验证，即在品牌跨界联合时，产品整合度对品牌联合评价有正向影响。 <xref ref-type="bibr" rid="oalib.147599-"></xref>Table 2. Comparison of consumers’ evaluation of co-brand under different product integration degreesTable 2. Comparison of consumers’ evaluation of co-brand under different product integration degrees 表2. 不同产品整合度下消费者对品牌联合评价的差异比较

整合度分组

个案数

平均值

标准差

T值

品牌联合评价

高整合度

61

2.811

0.678

−5.650***

低整合度

61

1.649

0.718
③ 中介效应检验。本文以跨界产品整合度为自变量、消费者感知价值为中介变量、品牌联合评价为因变量，运用PROCESS程序中的model 4，通过Bootstrap方法对感知价值的中介效应进行检验，其中控制性别、年龄等人口特征变量。结果显示，产品整合程度对品牌联合评价的总效应为0.942，95%置信区间为(0.642, 1.193)，直接效应为0.401，95%置信区间为(0.076, 0.723)，均不包括0，产品整合程度对消费者感知价值具有显著的正向影响[B = 1.231, 95%置信区间为(0.844, 1.713), SE = 0.231, t = 5.895, p < 0.01]，消费者感知价值对品牌联合评价具有显著正向影响[B = 0.449, 95%置信区间为(0.289, 0.589), SE = 0.071, t = 6.334, p < 0.01]，从产品整合度到感知价值，再到品牌联合评价，其中的间接效应为0.673，95%的置信区间(0.302, 0.937)，不含0，由此得以验证感知价值在产品整合程度与品牌联合评价关系里起到中介作用。 4. 结论与启示本文通过实证分析研究了处于品牌跨界联合中，产品整合度对品牌联合评价的影响关系，主要得到两个结论：首先，在品牌跨界联合时，相比于产品整合度较低的跨界组合，产品整合度高的跨界组合更能够带来积极的品牌联合评价，即产品整合度对品牌联合评价有正向影响；其次，消费者感知价值在跨界产品整合度对品牌联合评价的影响中起到中介作用。通过实证研究，发现产品整合度越高，越有利于消费者感知价值，同时当消费者感知价值以后会对品牌联合作出积极评价，即消费者感知价值在跨界产品整合度和品牌联合评价中起到中介作用。而SOR理论正是关于刺激对个体心理产生影响，从而产生反应的研究模型，因此本文基于SOR理论，在品牌跨界联合时，产品整合度高这一刺激源使得消费者根据偏好流畅性的心理会降低对跨界创新产品的不确定性，从而增强消费者对该类商品的接受度，并从中感知到联合的综合价值。当消费者感受到情绪价值或者社会价值时会产生积极反应，即较高的品牌联合评价，这不仅维持了消费者对原有品牌产品的忠诚度，又在一定程度上提升了品牌资产，为企业有针对性地进行品牌跨界联合提供了感知价值角度的理论支持。本文的研究为企业进行跨界创新实践活动提供了相应指导。首先，尽管市场上出现的跨界创新现象层出不穷，与不同的品牌进行跨界创新能够在短期内快速吸引消费者，并从长期唤起品牌活力，提升品牌创新能力，但是在这个过程中企业应该结合自身的发展情况和战略模式进行调整，不要跟风进行盲目跨界。合适的跨界能够带来正面效应，但是如果缺少跨界的前提情景和适宜时机，跨界将给企业的发展带来无论是品牌形象还是消费者受众都产生消极影响。其次，在品牌跨界联合时，除了考虑前期匹配性，还需要进行整合度的规划。许多企业在进行品牌联合时往往考虑合作双方固有的形象或者市场是否匹配，匹配性较大可以提升消费者的可接受度，但是也可能固化消费者认知。对于需要进行品牌跨界转型的企业来说，同质品牌联合对于公司的发展战略来说意义不大，如果品牌联合异质性较大，品牌联合发行起初可能会吸引眼球，赚取热度，收获许多受众；对于品牌资产不对等的双方来说，影响也不尽相同，但后期消费者感知的功能和形式方面的异质性过于突出，可能会引起消费者的排斥心理，进而降低消费者评价。企业可以通过提升联合产品在功能和形式方面的交融整合度，产品整合度高时消费者更加容易理解品牌联合的意义和价值，也能够避免品牌联合带来的不适感，降低消费者对冲击固有认知的排斥，进而更加理解品牌融合的真正目的以及给自身带来的价值，有利于提升消费者对品牌联合的认同感，对品牌联合做出积极评价，将不匹配产品转换为一次具有创新意义的匹配产品。最后，如果将跨界产品匹配性作为消费者是否接受的前提条件，那么整合度的提升将有益于消费者从中感受到该跨界联合所带来的综合价值。好的品牌联合除了考虑前期双方的联合匹配度，也要形成良好的产品整合度，如果前期的匹配度不能达到预期，那么可以通过后期从产品和功能方面对匹配联合整合度进行调整，从而激发消费者的购买意愿以及对该品牌联合的积极评价。所以企业在实践中要注意消费者感知价值在产品整合度对品牌联合评价中的中介作用，通过良好的整合促使消费者感知产品价值，进而提升品牌联合评价。 References Song, A., Lee, S.E. and Kim, J.H. (2022) Immunopathology and Immunotherapy of Inflammatory Skin Diseases. Immune Network, 22, e7. >https://doi.org/10.4110/in.2022.22.e7 Yamanaka, K. and Mizutani, H. (2015) “Inflammatory Skin March”: Il-1-Mediated Skin Inflammation, Atopic Dermatitis, and Psoriasis to Cardiovascular Events. Journal of Allergy and Clinical Immunology, 136, 823-824. >https://doi.org/10.1016/j.jaci.2015.06.009 Abuabara, K., Azfar, R.S., Shin, D.B., Neimann, A.L., Troxel, A.B. and Gelfand, J.M. (2010) Cause-Specific Mortality in Patients with Severe Psoriasis: A Population-Based Cohort Study in the U.K. British Journal of Dermatology, 163, 586-592. >https://doi.org/10.1111/j.1365-2133.2010.09941.x Silverberg, J.I. (2015) Association between Adult Atopic Dermatitis, Cardiovascular Disease, and Increased Heart Attacks in Three Population-Based Studies. Allergy, 70, 1300-1308. >https://doi.org/10.1111/all.12685 Andersen, Y.M.F., Egeberg, A., Gislason, G.H., Hansen, P.R., Skov, L. and Thyssen, J.P. (2016) Risk of Myocardial Infarction, Ischemic Stroke, and Cardiovascular Death in Patients with Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 138, 310-312.e3. >https://doi.org/10.1016/j.jaci.2016.01.015 Hu, S. and Lan, C.E. (2017) Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. International Journal of Molecular Sciences, 18, Article 2211. >https://doi.org/10.3390/ijms18102211 Gelfand, J.M., Dommasch, E.D., Shin, D.B., Azfar, R.S., Kurd, S.K., Wang, X., et al. (2009) The Risk of Stroke in Patients with Psoriasis. Journal of Investigative Dermatology, 129, 2411-2418. >https://doi.org/10.1038/jid.2009.112 Ruchti, F. (2024) Immunity to the Skin Commensal Yeast Malassezia in Healthy and Atopic Skin. Dissertation, University of Zurich. Vijaya Chandra, S.H., Srinivas, R., Dawson, T.L. and Common, J.E. (2021) Cutaneous Malassezia: Commensal, Pathogen, or Protector? Frontiers in Cellular and Infection Microbiology, 10, Article 614446. >https://doi.org/10.3389/fcimb.2020.614446 Pinto, L.M., Chiricozzi, A., Calabrese, L., Mannino, M. and Peris, K. (2022) Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis. Pharmaceutics, 14, Article 2767. >https://doi.org/10.3390/pharmaceutics14122767 Kim, H. (2022) Targeting Cytokines and Signaling Molecules Related to Immune Pathways in Atopic Dermatitis: Therapeutic Implications and Challenges. Archives of Pharmacal Research, 45, 894-908. >https://doi.org/10.1007/s12272-022-01421-2 Kolb, L. and Ferrer-Bruker, S.J. (2024) Atopic Dermatitis. StatPearls. Malajian, D. and Guttman-Yassky, E. (2015) New Pathogenic and Therapeutic Paradigms in Atopic Dermatitis. Cytokine, 73, 311-318. >https://doi.org/10.1016/j.cyto.2014.11.023 Fujii, M. (2020) Current Understanding of Pathophysiological Mechanisms of Atopic Dermatitis: Interactions among Skin Barrier Dysfunction, Immune Abnormalities and Pruritus. Biological and Pharmaceutical Bulletin, 43, 12-19. >https://doi.org/10.1248/bpb.b19-00088 Iskandar, I.Y.K., Parisi, R., Griffiths, C.E.M. and Ashcroft, D.M. (2020) Systematic Review Examining Changes over Time and Variation in the Incidence and Prevalence of Psoriasis by Age and Gender. British Journal of Dermatology, 184, 243-258. >https://doi.org/10.1111/bjd.19169 Sterry W. (2014) Plaque Psoriasis. In: Sterry, W., Sabat, R. and Philipp, S., eds., Psoriasis: Diagnosis and Management, John Wiley&Sons, 55-75. Harden, J.L., Krueger, J.G. and Bowcock, A.M. (2015) The Immunogenetics of Psoriasis: A Comprehensive Review. Journal of Autoimmunity, 64, 66-73. >https://doi.org/10.1016/j.jaut.2015.07.008 Boniface, K., Blom, B., Liu, Y. and De Waal Malefyt, R. (2008) From Interleukin-23 to T-Helper 17 Cells: Human T-Helper Cell Differentiation Revisited. Immunological Reviews, 226, 132-146. >https://doi.org/10.1111/j.1600-065x.2008.00714.x Morizane, S. and Gallo, R.L. (2012) Antimicrobial Peptides in the Pathogenesis of Psoriasis. The Journal of Dermatology, 39, 225-230. >https://doi.org/10.1111/j.1346-8138.2011.01483.x Hänsel, A., Günther, C., Ingwersen, J., Starke, J., Schmitz, M., Bachmann, M., et al. (2011) Human Slan (6-Sulfo LacNAc) Dendritic Cells Are Inflammatory Dermal Dendritic Cells in Psoriasis and Drive Strong T H17/T H1 T-Cell Responses. Journal of Allergy and Clinical Immunology, 127, 787-794.e9. >https://doi.org/10.1016/j.jaci.2010.12.009 Boekhout, T., et al. (2010) Malassezia and the Skin: Science and Clinical Practice. Springer, 1-319. Park, H.R., Oh, J.H., Lee, Y.J., Park, S.H., Lee, Y.W., Lee, S., et al. (2020) Inflammasome-Mediated Inflammation by Malassezia in Human Keratinocytes: A Comparative Analysis with Different Strains. Mycoses, 64, 292-299. >https://doi.org/10.1111/myc.13214 Lee, Y., Yassa, C., Park, S., Song, S.W., Jung, W.H., Lee, Y.W., et al. (2023) Interactions between Malassezia and New Therapeutic Agents in Atopic Dermatitis Affecting Skin Barrier and Inflammation in Recombinant Human Epidermis Model. International Journal of Molecular Sciences, 24, Article 6171. >https://doi.org/10.3390/ijms24076171 Nowicka, D. and Nawrot, U. (2019) Contribution of Malassezia spp. to the Development of Atopic Dermatitis. Mycoses, 62, 588-596. >https://doi.org/10.1111/myc.12913 Deng, R., Wang, X. and Li, R. (2023) Dermatophyte Infection: From Fungal Pathogenicity to Host Immune Responses. Frontiers in Immunology, 14, Article 1285887. >https://doi.org/10.3389/fimmu.2023.1285887 Sparber, F. and LeibundGut-Landmann, S. (2017) Host Responses to Malassezia spp. in the Mammalian Skin. Frontiers in Immunology, 8, Article 1614. >https://doi.org/10.3389/fimmu.2017.01614 Angiolella, L., Leone, C., Rojas, F., Mussin, J., de los Angeles Sosa, M. and Giusiano, G. (2017) Biofilm, Adherence, and Hydrophobicity as Virulence Factors in Malassezia Furfur. Medical Mycology, 56, 110-116. >https://doi.org/10.1093/mmy/myx014 Cheng, Y., Cong, J., Xu, J., Tang, L., Zhou, Z., Yang, X., et al. (2025) Research Progress on the Exacerbation of Lipid Metabolism by Malassezia and Its Impact on the Skin Barrier Function. Cosmetics, 12, Article 67. >https://doi.org/10.3390/cosmetics12020067 Ruchti, F. and Leibund Gut-Landmann, S. (2022) New Insights into Immunity to Skin Fungi Shape Our Understanding of Health and Disease. Parasite Immunology, 45, e12948. >https://doi.org/10.1111/pim.12948 Kanatoula, D.D., Bodner, E., Ghoreschi, K., Meier, K. and Solimani, F. (2024) Non‐biologic Immunosuppressive Drugs for Inflammatory and Autoimmune Skin Diseases. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 22, 400-421. >https://doi.org/10.1111/ddg.15270 Baldo, B.A. and Pham, N.H. (2020) Biologics: Monoclonal Antibodies for Non-Cancer Therapy, Cytokines, Fusion Proteins, Enzymes, and Hormones. In: Baldo, B.A. and Pham, N.H., Eds., Drug Allergy, Springer, 533-593. >https://doi.org/10.1007/978-3-030-51740-3_13 Akhter, S., Tasnim, F.M., Islam, M.N., Rauf, A., Mitra, S., Emran, T.B., et al. (2023) Role of Th17 and IL-17 Cytokines on Inflammatory and Auto-Immune Diseases. Current Pharmaceutical Design, 29, 2078-2090. >https://doi.org/10.2174/1381612829666230904150808 Ghoreschi, K., Balato, A., Enerbäck, C. and Sabat, R. (2021) Therapeutics Targeting the IL-23 and IL-17 Pathway in Psoriasis. The Lancet, 397, 754-766. >https://doi.org/10.1016/s0140-6736(21)00184-7 Mohd Noor, A.A., Azlan, M. and Mohd Redzwan, N. (2022) Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action. Biomedicines, 10, Article 498. >https://doi.org/10.3390/biomedicines10020498 Numerof, R.P. and Asadullah, K. (2006) Cytokine and Anti-Cytokine Therapies for Psoriasis and Atopic Dermatitis. BioDrugs, 20, 93-103. >https://doi.org/10.2165/00063030-200620020-00004 Sander, N., Stölzl, D., Fonfara, M., Hartmann, J., Harder, I., Suhrkamp, I., et al. (2024) Blockade of Interleukin-13 Signalling Improves Skin Barrier Function and Biology in Patients with Moderate-To-Severe Atopic Dermatitis. British Journal of Dermatology, 191, 344-350. >https://doi.org/10.1093/bjd/ljae138 Boyman, O., Comte, D. and Spertini, F. (2014) Adverse Reactions to Biologic Agents and Their Medical Management. Nature Reviews Rheumatology, 10, 612-627. >https://doi.org/10.1038/nrrheum.2014.123 Balato, A., Scala, E., Balato, N., Caiazzo, G., Di Caprio, R., Monfrecola, G., et al. (2017) Biologics That Inhibit the Th17 Pathway and Related Cytokines to Treat Inflammatory Disorders. Expert Opinion on Biological Therapy, 17, 1-12. >https://doi.org/10.1080/14712598.2017.1363884 Benson, J.M., Peritt, D., Scallon, B.J., Heavner, G.A., Shealy, D.J., Giles-Komar, J.M., et al. (2011) Discovery and Mechanism of Ustekinumab: A Human Monoclonal Antibody Targeting Interleukin-12 and Interleukin-23 for Treatment of Immune-Mediated Disorders. mAbs, 3, 535-545. >https://doi.org/10.4161/mabs.3.6.17815 Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., et al. (2020) The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Frontiers in Immunology, 11, Article 594735. >https://doi.org/10.3389/fimmu.2020.594735 Pescitelli, L., Rosi, E., Ricceri, F., Pimpinelli, N. and Prignano, F. (2020) Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis. Current Pharmaceutical Biotechnology, 22, 73-84. >https://doi.org/10.2174/1389201021666200611112755 Gosia, M., Doshi, G., Bagwe Parab, S. and Godad, A. (2025) Innovative Approaches to Psoriasis: Small Molecules Targeting Key Signaling Pathways. Immunological Investigations, 54, 457-493. >https://doi.org/10.1080/08820139.2025.2449960 Ryguła, I., Pikiewicz, W. and Kaminiów, K. (2023) Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions. Molecules, 28, Article 8064. >https://doi.org/10.3390/molecules28248064 Goldminz, A.M., Au, S.C., Kim, N., Gottlieb, A.B. and Lizzul, P.F. (2013) NF-κB: An Essential Transcription Factor in Psoriasis. Journal of Dermatological Science, 69, 89-94. >https://doi.org/10.1016/j.jdermsci.2012.11.002 Szymański, Ł., Skopek, R., Palusińska, M., Schenk, T., Stengel, S., Lewicki, S., et al. (2020) Retinoic Acid and Its Derivatives in Skin. Cells, 9, Article 2660. >https://doi.org/10.3390/cells9122660 Li, H., Zuo, J. and Tang, W. (2018) Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Frontiers in Pharmacology, 9, Article 1048. >https://doi.org/10.3389/fphar.2018.01048 Yang, Y., Li, S., Wang, Y., Zhao, Y. and Li, Q. (2022) Protein Tyrosine Kinase Inhibitor Resistance in Malignant Tumors: Molecular Mechanisms and Future Perspective. Signal Transduction and Targeted Therapy, 7, Article No. 329. >https://doi.org/10.1038/s41392-022-01168-8 Bissonnette, R., Saint‐Cyr Proulx, E., Jack, C. and Maari, C. (2023) Tapinarof for Psoriasis and Atopic Dermatitis: 15 Years of Clinical Research. Journal of the European Academy of Dermatology and Venereology, 37, 1168-1174. >https://doi.org/10.1111/jdv.18925 Jiraskova Zakostelska, Z., Reiss, Z., Tlaskalova-Hogenova, H. and Rob, F. (2023) Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved? Dermatology and Therapy, 13, 911-933. >https://doi.org/10.1007/s13555-023-00904-4 Koike, Y., Kuwatsuka, S., Motooka, D. and Murota, H. (2025) Dysbiosis of the Human Skin Mycobiome in Patients Receiving Systemic IL-23 Inhibitors. Allergology International, 74, 72-77. >https://doi.org/10.1016/j.alit.2024.06.003 Wijs, L.E.M., Nguyen, N.T., Kunkeler, A.C.M., Nijsten, T., Damman, J. and Hijnen, D.J. (2019) Clinical and Histopathological Characterization of Paradoxical Head and Neck Erythema in Patients with Atopic Dermatitis Treated with Dupilumab: A Case Series. British Journal of Dermatology, 183, 745-749. >https://doi.org/10.1111/bjd.18730 Soria, A., Du-Thanh, A., Seneschal, J., Jachiet, M., Staumont-Sallé, D. and Barbarot, S. (2019) Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis with Dupilumab. JAMA Dermatology, 155, 1312-1315. >https://doi.org/10.1001/jamadermatol.2019.2613 Kozera, E., Flora, A., Stewart, T., Gill, K., Xu, J., De La Vega, M.A., et al. (2023) Dupilumab-Associated Head and Neck Dermatitis Resolves Temporarily with Itraconazole Therapy and Rapidly with Transition to Upadacitinib, with Malassezia-Specific Immunoglobulin E Levels Mirroring Clinical Response. Journal of the American Academy of Dermatology, 88, 255-257. >https://doi.org/10.1016/j.jaad.2022.05.021 Umemoto, N., Kakurai, M., Matsumoto, T., Mizuno, K., Cho, O., Sugita, T., et al. (2024) Dupilumab Alters Both the Bacterial and Fungal Skin Microbiomes of Patients with Atopic Dermatitis. Microorganisms, 12, Article 224. >https://doi.org/10.3390/microorganisms12010224 de Aguiar Cordeiro, R., Reis, A.T., Lima, X.T.V., de Andrade, A.R.C., Aguiar, A.L.R., Portela, F.V.M., et al. (2022) Malassezia spp. and Candida spp. from Patients with Psoriasis Exhibit Reduced Susceptibility to Antifungals. Brazilian Journal of Microbiology, 54, 169-177. >https://doi.org/10.1007/s42770-022-00883-2 Park, M., Park, S. and Jung, W.H. (2021) Skin Commensal Fungus Malassezia and Its Lipases. Journal of Microbiology and Biotechnology, 31, 637-644. >https://doi.org/10.4014/jmb.2012.12048 Han, X., Ma, T., Wang, Q., Jin, C., Han, Y., Liu, G., et al. (2023) The Mechanism of Oxymatrine on Atopic Dermatitis in Mice Based on SOCS1/JAK-STAT3 Pathway. Frontiers in Pharmacology, 13, Article 1091090. >https://doi.org/10.3389/fphar.2022.1091090 Leong, C., Chan, J.W.K., Lee, S.M., Lam, Y.I., Goh, J.P.Z., Ianiri, G., et al. (2021) Azole Resistance Mechanisms in Pathogenic Malassezia furfur. Antimicrobial Agents and Chemotherapy, 65, e01975-20. >https://doi.org/10.1128/aac.01975-20 Leong, C., Chua, W., Chong, C., Lee, S.M., Maurer-Stroh, S., Jung, W.H., et al. (2025) Non-Synonymous ERG11 Mutations in M. restricta and M. arunalokei: Impact on Azole Susceptibility. Microbiology Spectrum, 13, e00007-25. >https://doi.org/10.1128/spectrum.00007-25 Siemieniuk, M., Czyzewska, U., Strumilo, S. and Tylicki, A. (2015) Thiamine Antivitamins—An Opportunity of Therapy of Fungal Infections Caused by Malassezia pachydermatis and Candida albicans. Mycoses, 59, 108-116. >https://doi.org/10.1111/myc.12441 Veerman, G.D.M., Hussaarts, K.G.A.M., Jansman, F.G.A., Koolen, S.W.L., van Leeuwen, R.W.F. and Mathijssen, R.H.J. (2020) Clinical Implications of Food-Drug Interactions with Small-Molecule Kinase Inhibitors. The Lancet Oncology, 21, e265-e279. >https://doi.org/10.1016/s1470-2045(20)30069-3